Department of Medical Genetics, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
MRC Cancer Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Nat Rev Cancer. 2021 Oct;21(10):619-637. doi: 10.1038/s41568-021-00377-7. Epub 2021 Jul 27.
Whole-genome sequencing has brought the cancer genomics community into new territory. Thanks to the sheer power provided by the thousands of mutations present in each patient's cancer, we have been able to discern generic patterns of mutations, termed 'mutational signatures', that arise during tumorigenesis. These mutational signatures provide new insights into the causes of individual cancers, revealing both endogenous and exogenous factors that have influenced cancer development. This Review brings readers up to date in a field that is expanding in computational, experimental and clinical directions. We focus on recent conceptual advances, underscoring some of the caveats associated with using the mutational signature frameworks and highlighting the latest experimental insights. We conclude by bringing attention to areas that are likely to see advancements in clinical applications.
全基因组测序将癌症基因组学领域带入了一个全新的领域。由于每个患者癌症中存在的数千种突变所提供的强大力量,我们能够辨别出在肿瘤发生过程中出现的通用突变模式,称为“突变特征”。这些突变特征为个体癌症的病因提供了新的见解,揭示了影响癌症发展的内源性和外源性因素。本综述使读者了解了该领域在计算、实验和临床方向上的扩展。我们重点介绍了最近的概念进展,强调了使用突变特征框架的一些注意事项,并突出了最新的实验见解。最后,我们提请注意可能在临床应用中取得进展的领域。
Nat Rev Cancer. 2021-10
Int J Cancer. 2023-4-15
DNA Repair (Amst). 2020-11
Nat Genet. 2024-3
Carcinogenesis. 2016-6
Nucleic Acids Res. 2025-7-8
Leukemia. 2025-7-9
Nat Commun. 2020-11-4